Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,371 active trials118 approved drugs1,150 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,734 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,407)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06533384 | PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC | recruiting | Phase 3 | 310 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06595108 | Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma(A-BEST) | recruiting | N/A | 33 | Yonsei UniversityOTHER | 1 | Nov 1, 2024 |
| NCT06669377 | TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT. | recruiting | — | 444 | Zhongda HospitalOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06667154 | Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy | recruiting | Phase 2 | 33 | Aline Fusco Fares, MDOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05468242 | Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy | recruiting | Phase 2 | 116 | Sun Yat-sen UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06664996 | Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT | recruiting | Phase 2 | 33 | West China HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT06662929 | Arabic PRO Measures for Head and Neck Cancer Radiotherapy.(PROMs) | recruiting | — | 125 | King Saud UniversityOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT05772455 | A Study of XZB-0004 in Patients With Solid Tumors | recruiting | Phase 1 | 128 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT05810571 | Comparison of Postoperative Analgesic Efficacy of the Erector Spina Plane Block and Quadratus Lumborum Block in Open Nephrectomy: a Prospective Randomized Clinical Study | recruiting | N/A | 60 | Kocaeli UniversityOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT05851534 | Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas(PROMISE-P) | recruiting | N/A | 2,575 | Maastricht University Medical CenterOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06084806 | Test-retest Evaluation of [18F]F-AraG PET | recruiting | Phase 2 | 10 | CellSight Technologies, Inc.INDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06107374 | Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG | recruiting | Phase 2 | 20 | CellSight Technologies, Inc.INDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT04322890 | Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation(PIKACHU) | recruiting | Phase 2 | 6,000 | Hunan Province Tumor HospitalOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT04335292 | Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge(OCELOT) | recruiting | Phase 2 | 200 | Mark VincentOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06652009 | Radical Radiotherapy Versus Radical Surgery for UTUC | recruiting | — | 60 | Peking University First HospitalOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05156060 | Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer | recruiting | Phase 1 / Phase 2 | 64 | Natalie LockneyOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05744219 | Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial(IRIS) | recruiting | Phase 3 | 338 | Jon UnossonOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05925764 | WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma | recruiting | — | 200 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06041009 | Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations | recruiting | — | 2,100 | Qilu Hospital of Shandong UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06649474 | Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1(HEPATOXALI) | recruiting | N/A | 100 | University Hospital, Clermont-FerrandOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT02292641 | Beyond TME Origins | recruiting | N/A | 383 | Imperial College LondonOTHER | 2 | Oct 17, 2024 | clinicaltrials |
| NCT03303547 | Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits(COMET) | recruiting | N/A | 200 | Imperial College LondonOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05501665 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | recruiting | Phase 1 / Phase 2 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04183712 | Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA | recruiting | Phase 2 | 102 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05882370 | TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study | recruiting | Phase 2 | 30 | Fei GaoOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06498479 | ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 460 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04049214 | Perioperative Mindfulness Proposal | recruiting | N/A | 24 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05286619 | A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)(PIPER) | recruiting | Phase 2 | 63 | University of MalayaOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05487391 | A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. | recruiting | Phase 3 | 632 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06538012 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06569498 | Neoadjuvant Triple Therapy for Resectable HCC(TALENP001) | recruiting | — | 20 | Fujian Provincial HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06602011 | Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002) | recruiting | — | 20 | Fujian Provincial HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06632431 | Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of Gynecology and Obestetrics (FIGO) | recruiting | — | 110 | Assiut UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06638593 | MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Masses ≤ 8cm.(MIRRORS-FROZEN) | recruiting | N/A | 40 | Royal Surrey County Hospital NHS Foundation TrustOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06640348 | Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer | recruiting | — | 70 | Anhui Provincial HospitalOTHER_GOV | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06642857 | Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer. | recruiting | — | 150 | Xiangdong ChengOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05440864 | Durvalumab and Tremelimumab in Resectable HCC((NEOTOMA)) | recruiting | Phase 2 | 28 | University Health Network, TorontoOTHER | 3 | Oct 10, 2024 | clinicaltrials |
| NCT06634966 | Segmentectomy for Solid-dominant Lung Cancer | recruiting | Phase 3 | 277 | Fudan UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05250648 | Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)(GECOP-MMC) | recruiting | Phase 4 | 216 | Hospital Universitario de FuenlabradaOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06623474 | Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma | recruiting | — | 900 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05766098 | Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY(PTC-ARRAY) | recruiting | — | 600 | Istituto Auxologico ItalianoOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06632093 | HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC | recruiting | — | 84 | First Hospital of China Medical UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT04571294 | Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy(PALN) | recruiting | N/A | 180 | Humanitas Hospital, ItalyOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT05203913 | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer(CNN-BC) | recruiting | Phase 2 | 32 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT05495152 | Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 219 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06623487 | The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer | recruiting | — | 30 | Ruijin HospitalOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06624098 | Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma | recruiting | N/A | 22 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05797415 | Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers(BLS) | recruiting | — | 25 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06463392 | Deep Learning-based sbORN Diagnostic Model | recruiting | — | 312 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Nov 4, 2024source: clinicaltrials